Source comparison
GHRP-6 vs Modern GH Secretagogues: Research Application Comparison
The following table compares Growth Hormone Releasing Peptide 6 to contemporary alternatives across key research parameters. Each compound's profile determines its optimal application context. GHRP-6 Baseline (1.0×) High (60–80% of subjects) Minimal at ≤2 mcg/
This comparison does not assign a generated winner or score.
- The following table compares Growth Hormone Releasing Peptide 6 to contemporary alternatives across key research parameters. Each compound's profile determines its optimal application context.
- GHRP-6
- Baseline (1.0×)
- High (60–80% of subjects)
- Minimal at ≤2 mcg/kg
- Moderate (15–25% reduction)
- Cachexia models, appetite research, first-generation GH secretagogue studies
- GHRP-2
- 1.1–1.3×
- Moderate (30–40% of subjects)
- General GH research with reduced appetite confounding
- Hexarelin
- 1.3–1.8×
- Moderate (30–50% of subjects)
- Significant at >2 mcg/kg
- High (40–60% reduction)
- Short-term high-potency GH research; cardiac tissue studies
- Ipamorelin
- 0.8–1.0×
- Minimal (<10% of subjects)
- Negligible
- Low (5–10% reduction)
- Selective GH pathway research, long-term studies, minimal side effect protocols
- CJC-1295 + Ipamorelin
- 1.5–2.5× (synergistic)
- Low (5–15% reduction)
- Sustained GH elevation studies, dual-axis amplification research, long-duration protocols
- Here's the honest answer: if your research protocol requires isolated GH pathway stimulation without ghrelin-mediated confounding, GHRP-6 is the wrong choice in 2026. Its value lies in specific contexts—appetite regulation studies, cachexia research, or historical comparison with first-generation secretagogues. For general GH research, modern alternatives like Ipamorelin or combination stacks like CJC-1295 Ipamorelin deliver equivalent or superior GH output with dramatically cleaner side effect profiles and less receptor desensitization over time.